Stockreport

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference [Yahoo...

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF — New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis — TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- [Read more]